Clinical trials: Congestive Heart Failure Chronic
Heart Failure
Effect of Intra-session Exercise Modes Sequence on Ventricular Function in Patients With Chronic Heart Failure
The aim of this study was to investigate the effect of intra-session exercise modes sequence on ventricular function in patients with chronic heart failure.
- Trial name
- NCT06626542
- Testing
- resistance and aerobic training exercises
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Heart Failure
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction
- Trial name
- NCT03281122
- Testing
- BMS-986224
- Where
- 18 sites in Czechia, Netherlands and 3 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Heart Failure, Non-ischemic Cardiomyopathy
The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure
The purpose of this prospective single-arm clinical study was to evaluate the safety and potential efficacy of intracoronary administration of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as an addition to…
- Conditions
- Chronic Heart Failure, Non-ischemic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
- Trial name
- RegenHeart (NCT04325594)
- Testing
- Intracoronary administration of umbilical cord-derived MSCs
- Where
- Kazakhstan
- Volunteers
- 30 people
- Sponsor
- The Research-Clinical Center for Cardiac Surgery and Transplantology LLP
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.
Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested.
- Trial name
- TAC-HFT-II (NCT02503280)
- Testing
- Autologous hMSCs, Autologous Human C-Kit CSCs II, Biosense Webster MyoStar NOGA Injection Catheter System
- Where
- United States
- Sponsor
- Joshua M Hare
Patient Engagement, Medication Optimization
Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF
The EPIC-HF study will test the effectiveness of a patient empowerment and activation for optimization of Heart Failure with reduced Ejection Fraction (HFrEF) medication plans.
- Conditions
- Patient Engagement, Medication Optimization, Heart Failure With Reduced Ejection Fraction, Patient Activation
- Trial name
- EPIC-HF (NCT03334188)
- Testing
- Patient engagement materials, No Intervention--Usual Care
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Colorado, Denver
Acute MI, Heart Failure
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and…
- Conditions
- Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
- Trial name
- CHAPERONE-CKM (NCT07403669)
- Testing
- CHAPERONE AI, CKMiq AI, Quality of Life
- Where
- 5 sites in United States, Sweden
- Volunteers
- 300 people
- Sponsor
- Aventyn, Inc.
Chronic Heart Failure, Hypertension
Nebivolol Versus Carvedilol in Patients With Heart Failure
BACKGROUND Beta-blockers improve left ventricular (LV) systolic function and prognosis in patients with chronic heart failure. Both carvedilol and nebivolol have hemodynamic and clinical benefits in chronic heart failure (CHF)…
- Trial name
- NCT00511888
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- IRCCS San Raffaele
Congestive Heart Failure, Pulmonary Hypertension
Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause
Pulmonary Hypertension (PH) is a disease that is characterized by vasoconstriction of small vessels of the lung. Many cases do have proliferation of endothelial cells within these vessels.
- Trial name
- NCT00893178
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- University of Leipzig
Chronic Heart Failure
Optimising Pacemaker Therapy for Contractility
The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF).
- Trial name
- OPT-C (NCT02964650)
- Testing
- Personalised rate-response settings
- Where
- United Kingdom
- Volunteers
- 83 people
- Sponsor
- University of Leeds
Chronic Kidney Diseases, Chronic Heart Failure
The Impact of CRT on Renal Function
The study is observational, prospective, including patients undergoing CRT-D / CRT-P implantation in the department of cardiology.
- Trial name
- NCT04516525
- Testing
- cardiac resynchronisation therapy (CRT) implantation
- Volunteers
- 74 people
- Sponsor
- University of Rzeszow
Chronic Heart Failure
Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure
The purpose of this study is to determine whether expressions of adipokines can provide prognostic information concerning patients with chronic heart failure.
- Trial name
- NCT02812797
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Heart Failure, Systolic
Physiological Effects of Lactate in Individuals With Chronic Heart Failure
Background: Lactate is continuously produced in the human body through two primary processes: glycolysis and microbial fermentation in the gastrointestinal tract.
- Trial name
- NCT06121323
- Testing
- Sodium lactate infusion, Sodium lactate ingestion
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Henrik Wiggers
Chronic Heart Failure, Iron Deficiency, Latent
The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)
Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients…
- Trial name
- ID-HFpEF (NCT05793996)
- Testing
- Ferinject, Diet therapy
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Endothelial Function, Beta Blocker
Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure
The aim of this study is to evaluate the effect of the two different beta blockers metoprolol and carvedilol on endothelial function in patients with either type two diabetes or chronic heart failure.
- Trial name
- NCT00497003
- Testing
- Treatment with either metoprolol or carvedilol
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Chronic Heart Failure
High Intensity Interval Training vs Moderate Intensity and Continuous Training in Chronic Heart Failure
Purpose: Exaggerated sympathetic nervous system (SNS) activity associated with low heart rate variability (HRV) is considered as a trigger of cardiac arrhythmias and sudden death.
- Trial name
- HRVFIT2 (NCT03603743)
- Testing
- exercise training in heart failure with HIIT
- Volunteers
- 32 people
- Sponsor
- Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens
Ischemic Cardiomyopathy
Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy
The study is testing the hypothesis, that the application of low dose erythropoetin beta (35 I.E./kg BW/week) for 6 months following successful coronary revascularization by PCI improves left ventricular remodeling as assessed by…
- Trial name
- EPOHeart (NCT00568542)
- Testing
- erythropoetin beta
- Where
- 2 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Heart Failure With Reduced Ejection Fraction
Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients
Statins have a protective effect in patients with established heart failure because of their lipid-lowering and pleiotropic effects.
- Trial name
- ASTRO-CHF (NCT05072054)
- Testing
- Atorvastatin Oral Tablet, Rosuvastatin Oral Tablet
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Heart Failure, Kidney Dysfunction
The Effects of Decreasing the Lasix Dose on the Cardiorenal System
The investigators' objective is to define the effects of decreasing the furosemide dose on heart, kidney and humoral function in people with compensated heart failure and kidney dysfunction and also in people with compensated…
- Trial name
- Aim1 (NCT00982423)
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients…
- Trial name
- NCT06651970
- Testing
- Acalabrutinib, Investigator's choice of treatment
- Where
- 23 sites in United States, Czechia and 4 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca